Alvotech develops and manufactures biosimilar medicines—follow-on versions of complex biologic drugs—intended to broaden access at lower cost than originator biologics. The company focuses on a pipeline of monoclonal antibodies and other biologics and partners with regional commercializers for distribution. Its customers are healthcare systems, pharmacies, and patients in markets where biosimilar competition is opening after patent expiry.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 132.8 | — | 109.7 | — |
| Q2 2025 | 173.2 | — | 32 | — |
| Q3 2025 | 113.7 | — | -5.3 | — |
| Q4 2025 | 166.6 | — | -108.5 | — |
| Q1 2026 | 105.9 | -20.3% | 1 | -99.1% |
All markets — KeepWinning global stock screener
Other companies on Stockholm: NCC AB (publ) (NCC A), NCC AB (publ) (NCC B), Kinnevik AB (KINV B), Attendo AB (publ) (ATT), AB Sagax (publ) (SAGA D), Atrium Ljungberg AB (publ) (ATRLJ B)